Status:
COMPLETED
A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting
Lead Sponsor:
Bayer
Conditions:
Contrast Enhancement in Magnetic Resonance Imaging
Eligibility:
All Genders
Brief Summary
This is an observational study, in which data associated with the wastage with the use of Gadavist single-dose vials, as compared to the wastage associated with the use of the Gadavist imaging bulk pa...
Eligibility Criteria
Inclusion
- A contrast-enhanced MRI using Gadavist for any indication at the study site during the study period
- Scheduled MRI to be performed in a study-designated room
Exclusion
- Administration of Gadavist from a single-dose prefilled syringe
- MRIs performed in the emergency setting
Key Trial Info
Start Date :
November 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 27 2023
Estimated Enrollment :
1602 Patients enrolled
Trial Details
Trial ID
NCT05350189
Start Date
November 3 2022
End Date
April 27 2023
Last Update
April 1 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15206
2
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, United States, 15224